CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0252 (clinicaltrials.gov NCT No: NCT01440998)
Title:Pilot and Translational Study of Dasatinib (IND #73969, NSC#732517), Paclitaxel and Carboplatin in Women with Advanced Stage and Recurrent Endometrial Cancer
Principal Investigator:Robert Coleman
Treatment Agent:Carboplatin; Dasatinib; Paclitaxel
Study Status:Open
Study Description:The goal of this clinical research study is to learn if dasatinib affects a
gene called EphA2 in the tumor.

Researchers also want to learn how often and how severe the side effects of
dasatinib may be when given with paclitaxel and carboplatin, and if and how
long this combination may help to control endometrial cancer.

Hide details for General InformationGeneral Information

Disease Group:Endometrium
Phase of Study:Phase 0
Treatment Agents:Carboplatin
Dasatinib
Paclitaxel
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:National Cancer Institute
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults